On the other hand, the lack of clinically relevant glucometabolic effects of exogenous GLP-2 can be perceived as an advantage in terms of off-target effects of current and future GLP-2–based drugs for the treatment of short bowel syndrome and obesity, respectively, until ongoing clinical trials providing longer-term safety data are completed. This evidence concerns the gene GCG and obesity disorder.